1456-P: 2022 State of Type 1 Diabetes in the U.S.—Real World T1D Exchange Multicenter Data from over 60,000 People

Abstract

Background: In response to sub-optimal type 1 diabetes (T1D) care data in the US, intensive quality improvement (QI) programs were implemented in the T1D Exchange QI collaborative (T1DX-QI) to improve outcomes for individuals with T1D. The aim of this analyses is to characterize the T1DX-QI patient population consisting of over 60,000 individuals with T1D Method: This cross-sectional analysis included 2022 electronic medical record (EMR) data of 60,915 individuals with T1D from 26 diabetes centers. Population attributes analyzed included demographics, duration of diabetes, glycemic outcomes and diabetes technology use. Result: In this population described in table 1, more adults ≥ 26 years of age were at A1c target goal (<7%) (34%), compared to children and adolescents (22%). Diabetes technology use was higher in the 6-13y age group (CGM: 64%, insulin pump: 53%) relative to adults 26-50y (CGM: 46%, insulin pump: 48%); whereas Hybrid Closed Loop System (HCLS) use was higher in adults 26-65y (13%) relative to children and younger adults 6-26y (6%). Self-reported Diabetes Ketoacidosis events were also higher in the younger age groups. Conclusion: This study reports characteristics of persons with T1D from a multi-center database and demonstrates that efforts are still needed to improve optimal management of diabetes. Table 1: T1DX-QI EMR T1D Data Distribution 2022 (N=60915) Disclosure O.Ebekozien: Advisory Panel; Medtronic, Research Support; Eli Lilly and Company, Dexcom, Inc. D.M.Maahs: Advisory Panel; Medtronic, LifeScan Diabetes Institute, MannKind Corporation, Consultant; Abbott, Research Support; Dexcom, Inc. .T1d exchange quality improvement collaborative (t1: n/a. N.Noor: None. L.Dimeglio: Advisory Panel; Merck & Co., Inc., Consultant; Abata Therapeutics, Vertex Pharmaceuticals Incorporated. M.Yau: None. R.Rapaport: None. J.Weissberg-benchell: Advisory Panel; Beta Bionics, Inc., Research Support; Beta Bionics, Inc. T.S.Hannon: Advisory Panel; Eli Lilly and Company. K.Mcnamara: None. K.Miller: Consultant; Dexcom, Inc. Funding The Leona M. and Harry B. Helmsley Charitable Trust